AbbVie Inc (ABBV NYSE) stock market data APIs
$215.922
0.55(0.3%)
as of January 16, 2026
Try our APIs with
free plan!
AbbVie Inc Financial Data Overview
Price chart is built with
Anychart
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta/Venclyxto to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic to treat neurologic diseases; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duopa and Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; and Qulipta for episodic and chronic migraine, as well as other neuroscience products. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. AbbVie Inc. has strategic partnership with OSE Immunotherapeutics. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Prev. Close
215.922
Open
216.4763
High
218.2628
Low
212.7084
52 wk Range
159.0544-241.1178
Market Cap
378 839 M
P/E Ratio
161.1654
Shares Outstanding
1 767 M
Revenue
59 644 M
EPS
1.86
Dividends (Yield)
0.0305
Beta
0.35
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with AbbVie Inc (top by weight)
Ticker
100-day Price Change
Weight
HDLB.US
ETRACS Monthly Pay 2xLeveraged US High Dividend Low Volatility ETN Series B
0.57
(3.72%)
9.80
SXLV.AS
SSgA SPDR ETFs Europe II Public Limited Company - SPDR S&P U.S. Health Care Select Sector UCITS ETF
3.18
(8.26%)
7.21
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get AbbVie Inc data using free add-ons & libraries
Get AbbVie Inc Fundamental Data
AbbVie Inc Fundamental data includes:
- Net Revenue: 59 644 M
- EBITDA: 29 519 M
- Earnings Per Share: 1
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-05
- EPS/Forecast: 3.27
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
AbbVie Inc News
New
AbbVie And Genmab: Phase 3 EPCORE DLBCL-1 Trial Shows PFS Gains But No Significant OS Benefit
(RTTNews) - AbbVie (ABBV) and Genmab A/S (GMAB) released results from the Phase 3 EPCORE DLBCL-1 trial evaluating epcoritamab, a subcutaneously administered, T-cell engaging bispecific antibody, versu...
Emmecell Appoints Ramin Valian as Chief Executive Officer to Advance Magnetic Cell Delivery Platform
MENLO PARK, Calif., January 16, 2026--(BUSINESS WIRE)--Emmecell, a clinical-stage biotechnology company pioneering magnetic cell delivery technologies for ophthalmic disease, today announced the appoi...
Mega-to-large cap healthcare stocks with the weakest earnings momentum
[Futuristic laboratory equipment. DNA research on computer screens] janiecbros/E+ via Getty Images As the earnings season kicks off, a review of mega to large cap healthcare stocks reveals several co...
Genmab down after trial data for AbbVie-partnered Epkinly in B-cell lymphoma
[Cancer cells] koto_feja/iStock via Getty Images Genmab (GMAB [https://seekingalpha.com/symbol/GMAB]) on Friday announced that its bispecific antibody epcoritamab, marketed as Epkinly in partnership ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
